pseudomonas infections

Summary

Summary: Infections with bacteria of the genus PSEUDOMONAS.

Top Publications

  1. pmc Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients
    Eric E Smith
    Genome Center, Program in Molecular and Cellular Biology, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 103:8487-92. 2006
  2. ncbi A signaling network reciprocally regulates genes associated with acute infection and chronic persistence in Pseudomonas aeruginosa
    Andrew L Goodman
    Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA
    Dev Cell 7:745-54. 2004
  3. pmc Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients
    Dieter Worlitzsch
    Institute of General and Environmental Hygiene, University of Tubingen, Tubingen, Germany
    J Clin Invest 109:317-25. 2002
  4. ncbi Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen
    C K Stover
    PathoGenesis Corporation, Seattle, Washington 98119, USA
    Nature 406:959-64. 2000
  5. pmc Direct interaction between sensor kinase proteins mediates acute and chronic disease phenotypes in a bacterial pathogen
    Andrew L Goodman
    Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genes Dev 23:249-59. 2009
  6. pmc Dynamics of Pseudomonas aeruginosa genome evolution
    Kalai Mathee
    Department of Molecular Microbiology and Immunology, College of Medicine, School of Computing and Information Sciences, College of Engineering, Florida International University, Miami, FL 33199, USA
    Proc Natl Acad Sci U S A 105:3100-5. 2008
  7. pmc The type III secretion system of Pseudomonas aeruginosa: infection by injection
    Alan R Hauser
    Departments of MicrobiologyImmunology and Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Nat Rev Microbiol 7:654-65. 2009
  8. ncbi Pseudomonas aeruginosa: all roads lead to resistance
    Elena B M Breidenstein
    Centre for Microbial Diseases and Immunity Research, Department of Microbiology and Immunology, University of British Columbia, Vancouver, Canada
    Trends Microbiol 19:419-26. 2011
  9. ncbi Pseudomonas aeruginosa: a formidable and ever-present adversary
    K G Kerr
    Department of Microbiology, Harrogate District Hospital, Lancaster Park Road, Harrogate, North Yorkshire HG2 7SX, UK
    J Hosp Infect 73:338-44. 2009
  10. pmc In vivo evidence of Pseudomonas aeruginosa nutrient acquisition and pathogenesis in the lungs of cystic fibrosis patients
    Mike S Son
    Department of Microbiology, College of Natural Sciences, University of Hawaii at Manoa, Honolulu, HI 96822, USA
    Infect Immun 75:5313-24. 2007

Detail Information

Publications306 found, 100 shown here

  1. pmc Genetic adaptation by Pseudomonas aeruginosa to the airways of cystic fibrosis patients
    Eric E Smith
    Genome Center, Program in Molecular and Cellular Biology, University of Washington, Seattle, WA 98195, USA
    Proc Natl Acad Sci U S A 103:8487-92. 2006
    ..aeruginosa strains present in advanced CF infections differ systematically from those of "wild-type" P. aeruginosa and that these differences may offer new opportunities for treatment of this chronic disease...
  2. ncbi A signaling network reciprocally regulates genes associated with acute infection and chronic persistence in Pseudomonas aeruginosa
    Andrew L Goodman
    Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA
    Dev Cell 7:745-54. 2004
    ..This study defines RetS as a pleiotropic regulator of multiple virulence phenotypes that orchestrates genes required for acute infection and genes associated with chronic persistence...
  3. pmc Effects of reduced mucus oxygen concentration in airway Pseudomonas infections of cystic fibrosis patients
    Dieter Worlitzsch
    Institute of General and Environmental Hygiene, University of Tubingen, Tubingen, Germany
    J Clin Invest 109:317-25. 2002
    ..These studies indicate that novel therapies for CF include removal of hypoxic mucus plaques and antibiotics effective against P. aeruginosa adapted to anaerobic environments...
  4. ncbi Complete genome sequence of Pseudomonas aeruginosa PAO1, an opportunistic pathogen
    C K Stover
    PathoGenesis Corporation, Seattle, Washington 98119, USA
    Nature 406:959-64. 2000
    ..We propose that the size and complexity of the P. aeruginosa genome reflect an evolutionary adaptation permitting it to thrive in diverse environments and resist the effects of a variety of antimicrobial substances...
  5. pmc Direct interaction between sensor kinase proteins mediates acute and chronic disease phenotypes in a bacterial pathogen
    Andrew L Goodman
    Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, Massachusetts 02115, USA
    Genes Dev 23:249-59. 2009
    ..These results suggest that multiple two-component systems found in a single bacterium can form multisensor signaling networks while maintaining specific phosphorelay pathways that remain insulated from detrimental cross-talk...
  6. pmc Dynamics of Pseudomonas aeruginosa genome evolution
    Kalai Mathee
    Department of Molecular Microbiology and Immunology, College of Medicine, School of Computing and Information Sciences, College of Engineering, Florida International University, Miami, FL 33199, USA
    Proc Natl Acad Sci U S A 105:3100-5. 2008
    ..Consequently, this organism can survive in a wide range of environmental reservoirs that can serve as sources of the infecting organisms...
  7. pmc The type III secretion system of Pseudomonas aeruginosa: infection by injection
    Alan R Hauser
    Departments of MicrobiologyImmunology and Medicine, Northwestern University, Chicago, Illinois 60611, USA
    Nat Rev Microbiol 7:654-65. 2009
    ..The features of this interesting secretion system have important implications for the pathogenesis of P. aeruginosa infections and for other type III secretion systems...
  8. ncbi Pseudomonas aeruginosa: all roads lead to resistance
    Elena B M Breidenstein
    Centre for Microbial Diseases and Immunity Research, Department of Microbiology and Immunology, University of British Columbia, Vancouver, Canada
    Trends Microbiol 19:419-26. 2011
    ....
  9. ncbi Pseudomonas aeruginosa: a formidable and ever-present adversary
    K G Kerr
    Department of Microbiology, Harrogate District Hospital, Lancaster Park Road, Harrogate, North Yorkshire HG2 7SX, UK
    J Hosp Infect 73:338-44. 2009
    ..A better understanding of the role of environmental reservoirs in pseudomonal infection will permit the development of new strategies and refinement of existing approaches to interrupt transmission from these sources to patients...
  10. pmc In vivo evidence of Pseudomonas aeruginosa nutrient acquisition and pathogenesis in the lungs of cystic fibrosis patients
    Mike S Son
    Department of Microbiology, College of Natural Sciences, University of Hawaii at Manoa, Honolulu, HI 96822, USA
    Infect Immun 75:5313-24. 2007
    ..aeruginosa in a natural infection in CF patients, and the results indicate several important aspects of P. aeruginosa pathogenesis, drug resistance, nutrient utilization, and general metabolism within the lungs of CF patients...
  11. pmc Quorum sensing and virulence of Pseudomonas aeruginosa during lung infection of cystic fibrosis patients
    Thomas Bjarnsholt
    Institute for International Health, Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark
    PLoS ONE 5:e10115. 2010
    ..As seen from the present data, we can conclude that P. aeruginosa and particularly the mucoid strains do not lose the QS regulation or the ability to produce rhamnolipids until the late stage of the chronic infection...
  12. ncbi Dynamics of adaptive microevolution of hypermutable Pseudomonas aeruginosa during chronic pulmonary infection in patients with cystic fibrosis
    Christina Hoboth
    Max von Pettenkofer Institut fur Hygiene und Medizinische Mikrobiologie, Germany
    J Infect Dis 200:118-30. 2009
    ..In patients with cystic fibrosis (CF), the emergence of hypermutable Pseudomonas aeruginosa drives the selection of P. aeruginosa variants that are efficiently adapted to the inflamed lungs of these patients...
  13. pmc Responses of Pseudomonas aeruginosa to low oxygen indicate that growth in the cystic fibrosis lung is by aerobic respiration
    Carolina Alvarez-Ortega
    Department of Microbiology, University of Washington, Seattle, WA 98195 7242, USA
    Mol Microbiol 65:153-65. 2007
    ..Any one of three high affinity terminal oxidases that P. aeruginosa encodes supported microaerobic growth. A triple mutant lacking all three of these oxidases failed to grow at low oxygen and formed abnormal biofilms...
  14. pmc Pseudomonas aeruginosa rugose small-colony variants have adaptations that likely promote persistence in the cystic fibrosis lung
    Melissa Starkey
    Department of Microbiology, University of Washington, Seattle, WA 98195 7242, USA
    J Bacteriol 191:3492-503. 2009
    ..RSCV traits such as increased exopolysaccharide production leading to antibiotic tolerance, altered metabolism, and reduced immunogenicity may contribute to increased persistence in biofilms and in the airways of CF lungs...
  15. ncbi The role of pyocyanin in Pseudomonas aeruginosa infection
    Gee W Lau
    Division of Pulmonary and Critical Care Medicine, and Department of Molecular Genetics, Biochemistry and Microbiology, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267 0564, USA
    Trends Mol Med 10:599-606. 2004
    ..aeruginosa during infection. In addition, few cellular pathways that are affected by PCN are known. This review briefly highlights recent advances that might clarify the role of PCN in P. aeruginosa pathogenesis...
  16. ncbi Evaluation of a new definition for chronic Pseudomonas aeruginosa infection in cystic fibrosis patients
    Tim W R Lee
    Leeds Regional Paediatric Cystic Fibrosis Centre, St James s Hospital, Leeds, UK
    J Cyst Fibros 2:29-34. 2003
    ....
  17. pmc C. elegans detects pathogen-induced translational inhibition to activate immune signaling
    Tiffany L Dunbar
    Division of Biological Sciences, University of California, San Diego, La Jolla, CA 92093, USA
    Cell Host Microbe 11:375-86. 2012
    ..Thus, translational inhibition, a common pathogenic strategy, can trigger activation of an immune surveillance pathway to provide host defense...
  18. pmc Host translational inhibition by Pseudomonas aeruginosa Exotoxin A Triggers an immune response in Caenorhabditis elegans
    Deborah L McEwan
    Department of Genetics, Harvard Medical School, and Department of Molecular Biology, Massachusetts General Hospital, Boston, MA 02114, USA
    Cell Host Microbe 11:364-74. 2012
    ..Thus, C. elegans has a surveillance mechanism to recognize ToxA through its effect on protein translation rather than by direct recognition of either ToxA or ribosylated EF2...
  19. pmc The broad host range pathogen Pseudomonas aeruginosa strain PA14 carries two pathogenicity islands harboring plant and animal virulence genes
    Jianxin He
    Department of Surgery, Harvard Medical School and Massachusetts General Hospital, Boston, MA 02114, USA
    Proc Natl Acad Sci U S A 101:2530-5. 2004
    ..The large set of "extra" virulence functions encoded by both PAPIs may contribute to the increased promiscuity of highly virulent P. aeruginosa strains, by directing additional pathogenic functions...
  20. pmc Genetic adaptation of Pseudomonas aeruginosa to the airways of cystic fibrosis patients is catalyzed by hypermutation
    A Mena
    Servicio de Microbiologia, Hospital Son Dureta, Instituto Universitario de Investigación en Ciencias de la Salud IUNICS, Palma de Mallorca, Spain
    J Bacteriol 190:7910-7. 2008
    ..aeruginosa genome evolution and adaptation during CRI...
  21. ncbi Identity and effects of quorum-sensing inhibitors produced by Penicillium species
    Thomas Bovbjerg Rasmussen
    Center for Biomedical Microbiology, BioCentrum DTU, Technical University of Denmark, DK 2800 Kgs Lyngby, Denmark
    Microbiology 151:1325-40. 2005
    ..In a mouse pulmonary infection model, Ps. aeruginosa was more rapidly cleared from the mice that were treated with patulin compared with the placebo group...
  22. pmc Mechanism of conversion to mucoidy in Pseudomonas aeruginosa infecting cystic fibrosis patients
    D W Martin
    Department of Microbiology, University of Texas Health Science Center, San Antonio 78284 7758
    Proc Natl Acad Sci U S A 90:8377-81. 1993
    ....
  23. ncbi Modulation of lung epithelial functions by Pseudomonas aeruginosa
    Gee W Lau
    Department of Medicine, University of Cincinnati College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267 0557, USA
    Trends Microbiol 13:389-97. 2005
    ..Understanding the complex interactions between the lung epithelium and P. aeruginosa might enable more effective therapeutic strategies against infection in cystic fibrosis and immuno-compromised individuals...
  24. pmc Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms
    Philip D Lister
    Department of Medical Microbiology and Immunology, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178, USA
    Clin Microbiol Rev 22:582-610. 2009
    ..aeruginosa, it is clear that we have much to learn about how this resourceful pathogen coregulates different resistance mechanisms to overcome the antibacterial challenges it faces...
  25. ncbi Bacterial hypermutation in cystic fibrosis, not only for antibiotic resistance
    A Oliver
    Servicio de Microbiología and Unidad de Investigación, Hospital Son Dureta, Instituto Universitario de Investigación en Ciencias de la Salud, Palma de Mallorca, Spain
    Clin Microbiol Infect 16:798-808. 2010
    ..Further prospective clinical studies are nevertheless still needed for an in-depth evaluation of the impact of mutators on disease progression and outcome...
  26. ncbi Pseudomonas aeruginosa biofilms in cystic fibrosis
    Niels Høiby
    Department of Clinical Microbiology 9301, Rigshospitalet, University of Copenhagen, Juliane Maries Vej 22, Copenhagen, Denmark
    Future Microbiol 5:1663-74. 2010
    ..aeruginosa biofilms. Biofilms can be prevented by early aggressive antibiotic prophylaxis or therapy, and they can be treated by chronic suppressive therapy...
  27. pmc Pseudomonas aeruginosa suppresses host immunity by activating the DAF-2 insulin-like signaling pathway in Caenorhabditis elegans
    Eric A Evans
    Department of Genetics, Stanford University School of Medicine, Stanford, California, United States of America
    PLoS Pathog 4:e1000175. 2008
    ..Our results reveal a new mechanism by which P. aeruginosa suppresses host immune defense...
  28. ncbi Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis
    Julia Emerson
    Division of Pulmonary Medicine, Department of Pediatrics, University of Washington, Seattle, USA
    Pediatr Pulmonol 34:91-100. 2002
    ..These findings confirm reports from previous smaller studies of outcomes among young children with CF, and highlight the potential to decrease the morbidity and mortality of young patients with CF through early intervention...
  29. ncbi Adaptation of Pseudomonas aeruginosa during persistence in the cystic fibrosis lung
    Michael Hogardt
    Bavarian Health and Food Safety Authority, Oberschleissheim, Germany
    Int J Med Microbiol 300:557-62. 2010
    ..aeruginosa variants, the antipseudomonal treatment, the prediction of the infectious disease state, and the development of efficient vaccines...
  30. pmc Metabolic network analysis of Pseudomonas aeruginosa during chronic cystic fibrosis lung infection
    Matthew A Oberhardt
    Department of Biomedical Engineering, University of Virginia, Box 800759, Health System, Charlottesville, Virginia 22908, USA
    J Bacteriol 192:5534-48. 2010
    ..Genes whose knockouts were either significantly growth reducing or lethal in silico were also identified for each time point and serve as hypotheses for future drug targeting efforts specific to the stages of disease progression...
  31. pmc Bacteriophages φMR299-2 and φNH-4 can eliminate Pseudomonas aeruginosa in the murine lung and on cystic fibrosis lung airway cells
    Debebe Alemayehu
    Teagasc Food Research Centre, Moorepark, Fermoy, Co Cork, Ireland
    MBio 3:e00029-12. 2012
    ....
  32. pmc Pseudomonas aeruginosa population structure revisited
    Jean Paul Pirnay
    Laboratory for Molecular and Cellular Technology, Burn Centre, Queen Astrid Military Hospital, Brussel, Belgium
    PLoS ONE 4:e7740. 2009
    ..aeruginosa "core lineage" and typically exhibited the exoS(+)/exoU(-) genotype and group B oprL and oprD alleles. This is to our knowledge the first report of an MST analysis conducted on a polyphasic data set...
  33. pmc Pathogen-host interactions in Pseudomonas aeruginosa pneumonia
    Ruxana T Sadikot
    Department of Veterans Affairs Medical Center, Nashville, Tennessee, USA
    Am J Respir Crit Care Med 171:1209-23. 2005
    ..aeruginosa infection. In addition to antibiotic therapy, strategies directed toward enhancing host defense and/or limiting excessive inflammation could be important to improve outcome in P. aeruginosa lung infections...
  34. ncbi Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients
    Thomas Bjarnsholt
    Department of International Health, Immunology and Microbiology, Faculty of Health Sciences, University of Copenhagen, Denmark
    Pediatr Pulmonol 44:547-58. 2009
    ..This strongly suggests that the conductive zone serves as a bacterial reservoir where the bacteria are organized in mucoid biofilms within the mucus, protected against antibiotics and host defenses...
  35. ncbi Genetic adaptation of Pseudomonas aeruginosa during chronic lung infection of patients with cystic fibrosis: strong and weak mutators with heterogeneous genetic backgrounds emerge in mucA and/or lasR mutants
    Oana Ciofu
    Department of International Health, Immunology and Microbiology, Faculty of Health Sciences, University of Copenhagen, Denmark
    Microbiology 156:1108-19. 2010
    ..Similar evolutionary pathways concordant with adaptive radiation were observed in different clonal lineages of P. aeruginosa from CF patients...
  36. ncbi The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections
    James A Driscoll
    Division of Pulmonary and Critical Care Medicine, Washington University School of Medicine, Saint Louis, Missouri, USA
    Drugs 67:351-68. 2007
    ..Multidrug-resistant P. aeruginosa may require treatment with less commonly used antibacterials (e.g. colistin), but newer anti-pseudomonal antibacterials are expected to be available in the near future...
  37. pmc Population structure of Pseudomonas aeruginosa from five Mediterranean countries: evidence for frequent recombination and epidemic occurrence of CC235
    Makaoui Maatallah
    Laboratoire d Analyse, Traitement et Valorisation des Polluants de l Environnement et des Produits, Faculte de Pharmacie, Monastir, Tunisia
    PLoS ONE 6:e25617. 2011
    ..P. aeruginosa isolates from the Mediterranean countries display an epidemic population structure, particularly dominated by ST235-O11, which has earlier also been coupled to the spread of ß-lactamases in many countries...
  38. ncbi Infection with transmissible strains of Pseudomonas aeruginosa and clinical outcomes in adults with cystic fibrosis
    Shawn D Aaron
    Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Ontario, Canada, K1H 8L6
    JAMA 304:2145-53. 2010
    ..Studies from Australia and the United Kingdom have shown that some patients with cystic fibrosis are infected with common transmissible strains of Pseudomonas aeruginosa...
  39. pmc Inescapable need for neutrophils as mediators of cellular innate immunity to acute Pseudomonas aeruginosa pneumonia
    Andrew Y Koh
    Channing Laboratory, Department of Medicine, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts, USA
    Infect Immun 77:5300-10. 2009
    ..aeruginosa lung infection from extremely small bacterial doses. There is an inescapable requirement for local PMN recruitment and activation to mediate innate immunity to P. aeruginosa lung infection...
  40. pmc Survey of resistance of Pseudomonas aeruginosa from UK patients with cystic fibrosis to six commonly prescribed antimicrobial agents
    T L Pitt
    Laboratory of HealthCare Associated Infection, Specialist and Reference Microbiology Division, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK
    Thorax 58:794-6. 2003
    ..Respiratory infection with Pseudomonas aeruginosa is very common in patients with cystic fibrosis (CF) but antimicrobial resistance rates of CF isolates across the UK are largely unknown...
  41. pmc Recent advances in the treatment of Pseudomonas aeruginosa infections in cystic fibrosis
    Niels Høiby
    Department of Clinical Microbiology 9301, Rigshospitalet and ISIM, University of Copenhagen, Juliane Maries Vej 22, DK 2100 Copenhagen, Denmark
    BMC Med 9:32. 2011
    ..aeruginosa infection did not improve lung function. Here I review the recent advances in the treatment of P. aeruginosa lung infections with a focus on inhalation treatments targeted at prophylaxis and chronic suppressive therapy...
  42. pmc Evolving stealth: genetic adaptation of Pseudomonas aeruginosa during cystic fibrosis infections
    Dao Nguyen
    Department of Medicine, University of Washington School of Medicine, 1959 Northeast Pacific Street, Room G 310, Seattle, WA 98195 7242, USA
    Proc Natl Acad Sci U S A 103:8305-6. 2006
  43. ncbi Pseudomonas aeruginosa bacteremia: risk factors for mortality and influence of delayed receipt of effective antimicrobial therapy on clinical outcome
    Cheol In Kang
    Department of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
    Clin Infect Dis 37:745-51. 2003
    ..079). There was a trend toward higher mortality as the length of delay increased. Delay in starting effective antimicrobial therapy for P. aeruginosa bacteremia tended to be associated with higher mortality...
  44. ncbi Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections
    A Roy-Burman
    Department of Anesthesia and Perioperative Care, Cardiovascular Research Institute, University of California, San Francisco, CA 94143-0542, USA
    J Infect Dis 183:1767-74. 2001
    ..A positive phenotype is a predictor of poor clinical outcome. In the future, such analyses may help distinguish potentially lethal infection from colonization and help determine appropriate therapy for critically ill patients...
  45. pmc Construction of a mini-Tn5-luxCDABE mutant library in Pseudomonas aeruginosa PAO1: a tool for identifying differentially regulated genes
    Shawn Lewenza
    Department of Microbiology and Immunology, University of British Columbia, Vancouver, British Columbia, Canada V6T 1Z4
    Genome Res 15:583-9. 2005
    ..This dual-purpose mutant library allows for functional and regulation studies and will serve as a resource for the research community to further our understanding of P. aeruginosa biology...
  46. ncbi Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa
    Alan R Hauser
    Department of Microbiology Immunology, Northwestern University, Chicago, IL, USA
    Crit Care Med 30:521-8. 2002
    ..The objective of this study was to determine whether this system contributes to disease severity in humans with ventilator-associated pneumonia...
  47. pmc Cooperation and virulence of clinical Pseudomonas aeruginosa populations
    Thilo Köhler
    Department of Microbiology and Molecular Medicine and Service of Infectious Diseases, University Hospital Geneva, 1211 Geneva, Switzerland
    Proc Natl Acad Sci U S A 106:6339-44. 2009
    ..These results demonstrate that social interactions can shape the short-term evolution and virulence of bacterial pathogens in humans, providing novel opportunities for therapy...
  48. pmc Effects of antibiotics on quorum sensing in Pseudomonas aeruginosa
    Mette E Skindersoe
    Biomedical Microbiology, BioSys, Technical University of Denmark, Kgs Lyngby DK 2800, Denmark
    Antimicrob Agents Chemother 52:3648-63. 2008
    ..The data suggest that the underlying mechanism may be mediated by changes in membrane permeability, thereby influencing the flux of N-3-oxo-dodecanoyl-L-homoserine lactone...
  49. pmc Distinct pathogenesis and host responses during infection of C. elegans by P. aeruginosa and S. aureus
    Javier E Irazoqui
    Program of Developmental Immunology, Department of Pediatrics, Massachusetts General Hospital, Department of Pediatrics, Harvard Medical School, Boston, Massachusetts, United States of America
    PLoS Pathog 6:e1000982. 2010
    ..aeruginosa nor the S. aureus-triggered response requires canonical TLR signaling, they imply the existence of unidentified mechanisms for pathogen detection in C. elegans, with potentially conserved roles also in mammals...
  50. ncbi Synthetic furanones inhibit quorum-sensing and enhance bacterial clearance in Pseudomonas aeruginosa lung infection in mice
    H Wu
    Department of Clinical Microbiology, University Hospital of Copenhagen Rigshospitalet, Juliane Marie Vej 22, Copenhagen Ø, DK 2100
    J Antimicrob Chemother 53:1054-61. 2004
    ..Furanone compounds capable of inhibiting bacterial quorum-sensing systems have been isolated from the marine macro alga Delisea pulchra...
  51. pmc Whole-genome sequence variation among multiple isolates of Pseudomonas aeruginosa
    David H Spencer
    The University of Washington Genome Center, Department of Medicine, University of Washington Children s Hospital and Regional Medical Center, Seattle, Washington 98195, USA
    J Bacteriol 185:1316-25. 2003
    ..aeruginosa backbone sequence while the strains addressed in this study possess additional genetic material that accounts for at least 10% of their genomes. Approximately half of these additional sequences are novel...
  52. pmc Development of a multilocus sequence typing scheme for the opportunistic pathogen Pseudomonas aeruginosa
    Barry Curran
    Department of Biological Sciences, University of Warwick, Coventry CV4 7AL, United Kingdom
    J Clin Microbiol 42:5644-9. 2004
    ..aeruginosa, the lack of a linkage between toxA type and serotype is not surprising and reveals the strength of the MLST approach for obtaining a better understanding of the epidemiology of P. aeruginosa...
  53. pmc Occurrence of hypermutable Pseudomonas aeruginosa in cystic fibrosis patients is associated with the oxidative stress caused by chronic lung inflammation
    Oana Ciofu
    Institute for Medical Microbiology and Immunology, University of Copenhagen, Panum Institute, IMMI 24 1, Blegdamsvej 3, 2200 Copenhagen N, Denmark
    Antimicrob Agents Chemother 49:2276-82. 2005
    ..The hypermutable phenotype can associate with mutations that confer adaptation of the bacteria in the lung and persistence of the infection...
  54. pmc Role of the type III secreted exoenzymes S, T, and Y in systemic spread of Pseudomonas aeruginosa PAO1 in vivo
    Russell E Vance
    Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA
    Infect Immun 73:1706-13. 2005
    ..Furthermore, our findings suggest that the effector-independent popB-dependent cytotoxicity that we and others have observed in vitro in macrophage cell lines may not be of great importance in vivo...
  55. pmc Pseudomonas aeruginosa virulence analyzed in a Dictyostelium discoideum host system
    Pierre Cosson
    Département de Morphologie, Universite de Geneve, Centre Medical Universitaire, CH 1211 Geneva 4, Switzerland
    J Bacteriol 184:3027-33. 2002
    ..aeruginosa should show reduced virulence. This result was confirmed in a rat model of acute pneumonia. Thus, D. discoideum could be used as a simple nonmammalian host system to assess pathogenicity of P. aeruginosa...
  56. ncbi Identification and characterization of transmissible Pseudomonas aeruginosa strains in cystic fibrosis patients in England and Wales
    Fiona W Scott
    Laboratory of HealthCare Associated Infection, Specialist and Reference Microbiology Division, Health Protection Agency, 61 Colindale Avenue, London NW9 5HT, UK
    J Med Microbiol 53:609-15. 2004
    ..These results emphasize the need for continued surveillance of P. aeruginosa genotypes in CF patients to provide informed infection control policy in treatment centres...
  57. ncbi MvfR, a key Pseudomonas aeruginosa pathogenicity LTTR-class regulatory protein, has dual ligands
    Gaoping Xiao
    Department of Surgery, Harvard Medical School, Massachusetts General Hospital, USA
    Mol Microbiol 62:1689-99. 2006
    ..These results uncover a novel biological role for HHQ; and provide novel insights on MvfR activation that may aid in the development of therapies that prevent or treat P. aeruginosa infections in humans...
  58. pmc Quality-controlled small-scale production of a well-defined bacteriophage cocktail for use in human clinical trials
    Maya Merabishvili
    Eliava Institute of Bacteriophage, Microbiology and Virology, Tbilisi, Georgia
    PLoS ONE 4:e4944. 2009
    ..The bacteriophage cocktail is currently being evaluated in a pilot clinical study cleared by a leading Medical Ethical Committee...
  59. pmc Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis
    Karen S McCoy
    Ohio State University, Nationwide Children s Hospital, Columbus, OH 43205, USA
    Am J Respir Crit Care Med 178:921-8. 2008
    ....
  60. ncbi Pseudomonas aeruginosa in chronic obstructive pulmonary disease
    Timothy F Murphy
    Medical Research 151, Buffalo Veterans Affairs Medical Center, 3495 Bailey Avenue, Buffalo, NY 14215, USA
    Am J Respir Crit Care Med 177:853-60. 2008
    ..Pseudomonas aeruginosa is isolated from adults with chronic obstructive pulmonary disease (COPD) in cross-sectional studies. However, patterns of carriage and the role of P. aeruginosa in COPD are unknown...
  61. pmc Instantaneous within-patient diversity of Pseudomonas aeruginosa quorum-sensing populations from cystic fibrosis lung infections
    Cara N Wilder
    Department of Microbiology, Oregon State University, Corvallis, Oregon 97331, USA
    Infect Immun 77:5631-9. 2009
    ..The observed diversity also shows that conclusions about the properties of P. aeruginosa QS populations in individual CF infections cannot be drawn from the characterization of one or a few selected isolates...
  62. ncbi Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence
    Alessandra Bragonzi
    Infections and Cystic Fibrosis Unit, Division of Immunology, Transplantation and Infectious Diseases, San Raffaele Scientific Institute, Milano, Italy
    Am J Respir Crit Care Med 180:138-45. 2009
    ..During long-term lung infection in patients with cystic fibrosis (CF), Pseudomonas aeruginosa strains develop mutations leading to clonal expansion. This microevolution is believed to be correlated with a reduced virulence...
  63. ncbi Pseudomonas aeruginosa infection and inflammation during contact lens wear: a review
    Mark D P Willcox
    Institute for Eye Research, Vision CRC and School of Optometry and Vision Science, University of New South Wales, Australia
    Optom Vis Sci 84:273-8. 2007
    ..This can ultimately lead to scarring and vision loss...
  64. pmc Molecular epidemiology of metallo-beta-lactamase-producing Pseudomonas aeruginosa isolates from Norway and Sweden shows import of international clones and local clonal expansion
    Orjan Samuelsen
    Reference Centre for Detection of Antimicrobial Resistance, Department of Microbiology and Infection Control, University Hospital of North Norway, N 9038 Tromsø, Norway
    Antimicrob Agents Chemother 54:346-52. 2010
    ..The findings suggest that both import of successful international clones and local clonal expansion contribute to the emergence of MBL-producing P. aeruginosa in Scandinavia...
  65. ncbi N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms
    K Riedel
    Department of Microbiology, TUM, Am Hochanger 4, D-85350 Freising, Germany
    Microbiology 147:3249-62. 2001
    ....
  66. ncbi Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa
    Nityakalyani Srinivas
    Chemistry Department, University of Zurich, Winterthurerstrasse 190, 8057 Zurich, Switzerland
    Science 327:1010-3. 2010
    ..The peptidomimetic showed potent antimicrobial activity in a mouse septicemia infection model. Drug-resistant strains of Pseudomonas are a serious health problem, so this family of antibiotics may have important therapeutic applications...
  67. pmc Wide dispersion of ST175 clone despite high genetic diversity of carbapenem-nonsusceptible Pseudomonas aeruginosa clinical strains in 16 Spanish hospitals
    María García-Castillo
    Servicio de Microbiologia, Hospital Universitario Ramon y Cajal, Ctra Colmenar Km 9 1, 28034 Madrid, Spain
    J Clin Microbiol 49:2905-10. 2011
    ..aeruginosa clones at high risk for epidemic spread, such as the Liverpool, Manchester, and Melbourne clones previously found in cystic fibrosis patients and ST235 in the nosocomial setting...
  68. ncbi Longitudinal assessment of Pseudomonas aeruginosa in young children with cystic fibrosis
    J L Burns
    Division of Infectious Disease, Department of Pediatrics, University of Washington and Children s Hospital and Regional Medical Center, Seattle, WA 98105, USA
    J Infect Dis 183:444-52. 2001
    ..On the basis of combined culture and serologic results, 97.5% of patients had evidence of infection by age 3 years, which suggests that P. aeruginosa infection occurs early in CF and may be intermittent or undetectable by culture...
  69. pmc The accessory genome of Pseudomonas aeruginosa
    Vanderlene L Kung
    Department of Microbiology Immunology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Microbiol Mol Biol Rev 74:621-41. 2010
    ..aeruginosa accessory genome have yet to be determined, rapid progress is being made, and a clearer understanding of the role of the P. aeruginosa accessory genome in ecology and infection is emerging...
  70. pmc TLR4 and TLR5 on corneal macrophages regulate Pseudomonas aeruginosa keratitis by signaling through MyD88-dependent and -independent pathways
    Yan Sun
    Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, OH 44106, USA
    J Immunol 185:4272-83. 2010
    ..IL-1α and IL-1β are also produced, which activate an IL-1R1/MyD88-positive feedback loop in macrophages and IL-1R on other resident cells in the cornea...
  71. pmc Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial
    Michael W Konstan
    Rainbow Babies and Children s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH, USA
    J Cyst Fibros 10:54-61. 2011
    ....
  72. ncbi Clonal epidemiology of Pseudomonas aeruginosa in cystic fibrosis
    Nina Cramer
    Klinik für Pädiatrische Pneumologie und Neonatologie, Medizinische Hochschule Hannover, Germany
    Int J Med Microbiol 300:526-33. 2010
    ..The measures to prevent and to treat the Pseudomonas infections in CF have been considerably improved during the last 20 years...
  73. pmc Pseudomonas aeruginosa exotoxin pyocyanin causes cystic fibrosis airway pathogenesis
    Charles C Caldwell
    Department of Surgery, University of Cincinnati College of Medicine, Cincinnati, Ohio, USA
    Am J Pathol 175:2473-88. 2009
    ..In summary, this study establishes that PCN is an important P. aeruginosa virulence factor capable of directly inducing pulmonary pathophysiology in mice, consistent with changes observed in CF and other bronchiectasis lungs...
  74. ncbi Pseudomonas aeruginosa population diversity and turnover in cystic fibrosis chronic infections
    Eilidh Mowat
    Institute of Infection and Global Health, University of Liverpool, Liverpool L69 3GA, UK
    Am J Respir Crit Care Med 183:1674-9. 2011
    ..Pseudomonas aeruginosa isolates from chronic cystic fibrosis lung infections display multiple phenotypes indicating extensive population diversity...
  75. ncbi Pathophysiology and management of pulmonary infections in cystic fibrosis
    Ronald L Gibson
    Department of Pediatrics, University of Washington School of Medicine, Children s Hospital, Seattle, WA 98125, USA
    Am J Respir Crit Care Med 168:918-51. 2003
    ..In addition, the article discusses infection control policies, therapies to optimize airway clearance and reduce inflammation, and potential future therapies...
  76. pmc Bacterial keratitis: predisposing factors, clinical and microbiological review of 300 cases
    T Bourcier
    Quinze Vingts National Center of Ophthalmology, Paris, France
    Br J Ophthalmol 87:834-8. 2003
    ..To identify predisposing factors and to define clinical and microbiological characteristics of bacterial keratitis in current practice...
  77. ncbi Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella
    J J Rahal
    Department of Medicine, New York Hospital Medical Center of Queens and Cornell University Medical College, Flushing 11355, USA
    JAMA 280:1233-7. 1998
    ..Resistance to most or all cephalosporin antibiotics in Klebsiella species has developed in many European and North American hospitals during the past 2 decades...
  78. pmc Tobramycin and FDA-approved iron chelators eliminate Pseudomonas aeruginosa biofilms on cystic fibrosis cells
    Sophie Moreau-Marquis
    Department of Physiology, Dartmouth Medical School, Hanover, NH 03755, USA
    Am J Respir Cell Mol Biol 41:305-13. 2009
    ..These data suggest that the combined use of tobramycin and FDA-approved iron chelators may be an effective therapy to treat patients with CF and other lung disease characterized by antibiotic-resistant P. aeruginosa biofilms...
  79. ncbi Garlic blocks quorum sensing and promotes rapid clearing of pulmonary Pseudomonas aeruginosa infections
    Thomas Bjarnsholt
    Centre for Biomedical Microbiology, BioCentrum, Technical University of Denmark, DK 2800 Lyngby, Denmark
    Microbiology 151:3873-80. 2005
    ..The results indicate that a QS-inhibitory extract of garlic renders P. aeruginosa sensitive to tobramycin, respiratory burst and phagocytosis by PMNs, as well as leading to an improved outcome of pulmonary infections...
  80. pmc Pseudomonas aeruginosa evasion of phagocytosis is mediated by loss of swimming motility and is independent of flagellum expression
    Eyal Amiel
    Department of Microbiology and Immunology, Dartmouth Medical School, Lebanon, New Hampshire 03756, USA
    Infect Immun 78:2937-45. 2010
    ..These findings provide an explanation for the well-documented observation of nonmotility in clinical P. aeruginosa isolates and for how this phenotype confers upon the bacteria an advantage in the context of immune evasion...
  81. ncbi Corneal response to Pseudomonas aeruginosa infection
    Linda Dondero Hazlett
    Department of Anatomy and Cell Biology, Wayne State University, 540 E Canfield, Room 7341, Detroit, MI 48201, USA
    Prog Retin Eye Res 23:1-30. 2004
    ..Future studies will be aimed at better defining the role of Toll receptors, neuropeptides (as unconventional modulators of the immune response) and exploitation of disease control by new techniques, such as RNA silencing...
  82. pmc Impact of Pseudomonas aeruginosa genomic instability on the application of typing methods for chronic cystic fibrosis infections
    Joanne L Fothergill
    Division of Medical Microbiology, University of Liverpool, Duncan Building, Daulby Street, Liverpool L69 3GA, United Kingdom
    J Clin Microbiol 48:2053-9. 2010
    ....
  83. pmc A quorum sensing regulated small volatile molecule reduces acute virulence and promotes chronic infection phenotypes
    Meenu Kesarwani
    Department of Surgery, Harvard Medical School and Massachusetts General Hospital, Boston, Massachusetts, United States of America
    PLoS Pathog 7:e1002192. 2011
    ..aeruginosa. We propose that 2-AA mediates changes in a subpopulation of cells that facilitate the exploitation of dynamic host environments and promote gene expression changes that favor chronic infections...
  84. ncbi Levofloxacin inhalation solution (MP-376) in patients with cystic fibrosis with Pseudomonas aeruginosa
    David E Geller
    Nemours Children s Clinic, Orlando, FL 32801, USA
    Am J Respir Crit Care Med 183:1510-6. 2011
    ..New treatment options for CF pulmonary infections are needed...
  85. ncbi Relationship between cystic fibrosis respiratory tract bacterial communities and age, genotype, antibiotics and Pseudomonas aeruginosa
    Vanja Klepac-Ceraj
    Department of Microbiology and Molecular Genetics, Harvard Medical School, Boston, MA 02115, USA
    Environ Microbiol 12:1293-303. 2010
    ..aeruginosa, regardless of antibiotic exposure. This suggests that community composition might be a better predictor of disease progression than the presence of P. aeruginosa alone and deserves further study...
  86. pmc Hemolytic phospholipase C inhibition protects lung function during Pseudomonas aeruginosa infection
    Matthew J Wargo
    Department of Microbiology and Molecular Genetics, University of Vermont College of Medicine, Burlington, VT 05405, USA
    Am J Respir Crit Care Med 184:345-54. 2011
    ..Decreased lung function contributes significantly to morbidity and mortality during P. aeruginosa infection, and damage inflicted by P. aeruginosa virulence factors contributes to lung function decline...
  87. pmc Role of bacteriocins in mediating interactions of bacterial isolates taken from cystic fibrosis patients
    Suphan Bakkal
    Department of Biology, University of Massachusetts Amherst, 611 North Pleasant Street, Amherst, MA 01003, USA
    Microbiology 156:2058-67. 2010
    ..These data suggest that bacteriocin-based inhibition may play a role in governing Pa and Bcc interactions in the CF lung and may, therefore, offer a novel approach to mediating these often fatal infections...
  88. ncbi Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units
    Jose Antonio Martinez
    Department of Infectious Diseases, Hospital Clinic, IDIBAPS University of Barcelona, Spain
    Crit Care Med 34:329-36. 2006
    ..To compare a mixing vs. a cycling strategy of use of anti-Pseudomonas antibiotics on the acquisition of resistant Gram-negative bacilli in the critical care setting...
  89. pmc The single-nucleotide resolution transcriptome of Pseudomonas aeruginosa grown in body temperature
    Omri Wurtzel
    Department of Molecular Genetics, Weizmann Institute of Science, Rehovot, Israel
    PLoS Pathog 8:e1002945. 2012
    ..Our work identifies regulatory features of P. aeruginosa genes whose products play a role in environmental adaption during infection and provides a reference transcriptional landscape for this pathogen...
  90. pmc Purification of outer membrane vesicles from Pseudomonas aeruginosa and their activation of an IL-8 response
    Susanne J Bauman
    Duke University Medical Center, Department of Biochemistry, Box 3711, Research Drive, Durham, NC 27710, USA
    Microbes Infect 8:2400-8. 2006
    ..These results suggest that P. aeruginosa colonizing the CF lung may produce vesicles with a particular composition and that the vesicles could contribute to inflammation...
  91. pmc Role of the membrane localization domain of the Pseudomonas aeruginosa effector protein ExoU in cytotoxicity
    Jeff L Veesenmeyer
    Department of Microbiology Immunology, Northwestern University, Chicago, Illinois, USA
    Infect Immun 78:3346-57. 2010
    ..These findings add to our understanding of the role of the MLD in ExoU-mediated virulence...
  92. ncbi Quantification of methyl thiocyanate in the headspace of Pseudomonas aeruginosa cultures and in the breath of cystic fibrosis patients by selected ion flow tube mass spectrometry
    Violetta Shestivska
    J Heyrovsky Institute of Physical Chemistry, Academy of Science of the Czech Republic, Prague, Czech Republic
    Rapid Commun Mass Spectrom 25:2459-67. 2011
    ..SIFT-MS was also used to analyze the breath of 28 children with CF and the concentrations of methyl thiocyanate were found to be in the range 2-21 ppbv (median 7 ppbv)...
  93. ncbi Longitudinal development of mucoid Pseudomonas aeruginosa infection and lung disease progression in children with cystic fibrosis
    Zhanhai Li
    Department of Pediatrics, University of Wisconsin, Madison 53705 2221, USA
    JAMA 293:581-8. 2005
    ....
  94. ncbi Pseudomonas aeruginosa and Pseudomonas putida outbreak associated with contaminated water outlets in an oncohaematology paediatric unit
    C Aumeran
    CHU Clermont Ferrand, Hopital Gabriel Montpied, Service d Hygiène Hospitalière, Clermont Ferrand, France and Univ Clermont 1, UFR Medecine, EA 3843, Laboratoire de Virologie, Clermont Ferrand, France
    J Hosp Infect 65:47-53. 2007
    ..Following these measures, no Pseudomonas spp. have since been isolated in clinical or environmental samples from the ward...
  95. ncbi Colistin-tobramycin combinations are superior to monotherapy concerning the killing of biofilm Pseudomonas aeruginosa
    Gloria Herrmann
    Institute of Medical Microbiology and Hygiene, Universitatsklinikum, University of Tubingen, Tubingen, Germany
    J Infect Dis 202:1585-92. 2010
    ..We tested the ability of colistin sulphate-tobramycin combinations and single antibiotics to kill P. aeruginosa biofilms...
  96. pmc Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously
    Catherine Llanes
    Laboratoire de Bacteriologie, Hopital Jean Minjoz, Besancon, France
    Antimicrob Agents Chemother 48:1797-802. 2004
    ..These data show that clinical isolates are able to broaden their drug resistance profiles by coexpressing two Mex efflux pumps and suggest the existence of additional regulators for MexAB-OprM and MexXY...
  97. pmc Type III secretion phenotypes of Pseudomonas aeruginosa strains change during infection of individuals with cystic fibrosis
    Manu Jain
    Department of Medicine, Northwestern University, Chicago, IL 60611, USA
    J Clin Microbiol 42:5229-37. 2004
    ..Together, these findings indicate that following infection of cystic fibrosis patient airways, P. aeruginosa strains gradually change from a type III protein secretion-positive phenotype to a secretion-negative phenotype...
  98. pmc Inhibitors of pathogen intercellular signals as selective anti-infective compounds
    Biliana Lesic
    Department of Surgery, Microbiology and Molecular Genetics, Harvard Medical School, Massachusetts General Hospital, Boston, Massachusetts, USA
    PLoS Pathog 3:1229-39. 2007
    ..These compounds provide a starting point for the design and development of selective anti-infectives that restrict human P. aeruginosa pathogenesis, and possibly other clinically significant pathogens...
  99. pmc Analysis of Pseudomonas aeruginosa diguanylate cyclases and phosphodiesterases reveals a role for bis-(3'-5')-cyclic-GMP in virulence
    Hemantha Kulasakara
    Department of Microbiology and Molecular Genetics, Harvard Medical School, 200 Longwood Avenue, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 103:2839-44. 2006
    ....
  100. ncbi Anaerobic physiology of Pseudomonas aeruginosa in the cystic fibrosis lung
    Max Schobert
    Institute of Microbiology, Technische Universitat Braunschweig, Germany
    Int J Med Microbiol 300:549-56. 2010
    ..Growth in these oxygen-limited environments induces a drastic physiological change in P. aeruginosa, like increased alginate production and alterations in the outer membrane, which contribute to an increased antibiotic tolerance...
  101. pmc Hypermutation is a key factor in development of multiple-antimicrobial resistance in Pseudomonas aeruginosa strains causing chronic lung infections
    María D Maciá
    Servicio de Microbiologia, Hospital Son Dureta, C Andrea Doria No 55, 07014 Palma de Mallorca, Spain
    Antimicrob Agents Chemother 49:3382-6. 2005
    ..Furthermore, hypermutation is found to be a key factor for the development of multiple-antimicrobial resistance, and therefore these findings are expected to have important consequences for the treatment of chronic infections...

Research Grants64

  1. Boosting Innate Immunity Through HIF to Treat Antibiotic-Resistant Infections
    ROBERT ALAN SHALWITZ; Fiscal Year: 2013
    ..mice will be used to assess the role of the transcriptional control pathway in control of MRSA and Pseudomonas infections in skin, skin wounds, and pneumonia models of infection...
  2. Development of an antimicrobial peptide therapeutic for Pseudomonas infections
    HELOISE ANNE PEREIRA; Fiscal Year: 2011
    ..Identifying new therapeutics with strong antimicrobial activity and low propensity to induce resistance will be of great public health importance. ..
  3. Supporting New Faculty Recruitment Through Biomedical Research Core Center
    David H Ingbar; Fiscal Year: 2010
    ..infections, specifically exploring the role of a polyamine precursor, agmatine, that is important in Pseudomonas infections and in biofilm formation. He obtained his Microbiology PhD under the mentorship of Dr...
  4. Hyperacidification and Pseudomonas infections in CF
    Vojo Deretic; Fiscal Year: 2006
    ..abstract_text> ..
  5. BRONCHOPULMONARY INFECTION--THE ROLE OF MUCIN
    Reuben Ramphal; Fiscal Year: 1999
    ..Thus, the long term objective of this work is to develop new approaches to the prevention of chronic Pseudomonas infections based on interference with bacterial colonization of the respiratory tract...
  6. PSEUDOMONAS AERUGINOSA EXOTOXIN A
    ROCKFORD DRAPER; Fiscal Year: 1993
    ..A of Pseudomonas aeruginosa, a protein of molecular weight 66,583, is an important virulence factor in Pseudomonas infections. The toxin is also a model system for preparation and characterization of hybrid toxins that may have ..
  7. PSEUDOMONAS EYE INFECTION - AN EXPERIMENTAL MODEL
    Richard Berk; Fiscal Year: 1992
    ..b>Pseudomonas infections of the cornea commonly occur following corneal trauma or wounds resulting from industrial accidents, in ..
  8. MOLECULAR MECHANISM OF PSEUDOMONAS INVASION OF CELLS
    BARBARA KAZMIERCZAK; Fiscal Year: 2001
    ..Despite appropriate antibiotic therapy, Pseudomonas infections are associated with high rates of mortality...
  9. Lipid/DNA/Antigen Complexes for Pseudomonas vaccines
    Jeff Fairman; Fiscal Year: 2004
    ..Because of the types of patients at risk, Pseudomonas infections usually occur in a hospital setting...
  10. Host genes required for P. aeruginosa pathogenesis
    Vincent Lee; Fiscal Year: 2004
    The goal of this research is to identify genes and pathways of mammalian host that play a role during Pseudomonas infections. Specifically, the mechanism of action of a class of proteins produced by Pseudomonas aeruginosa, an ..
  11. Susceptibility Testing, Treatment Choices, and Outcomes of MDR-GNB Infections
    Lisa Saiman; Fiscal Year: 2009
    ..Carefully conducted observational studies and clinically relevant in vitro antimicrobial susceptibility testing, hold the greatest promise to improve the treatment of patients infected with mutidrug-resistant organisms. ..
  12. BACTERIAL INDUCTION OF CYTOKINE EXPRESSION IN THE LUNG
    Alice Prince; Fiscal Year: 2005
    ....
  13. CF EPITHELIAL CELLS: INTERACTIONS WITH PSEUDOMONAS
    Alice Prince; Fiscal Year: 2005
    ..Using genetically defined mutants, the contribution of PLC to epithelial damage in normal and CF cells will be examined. ..
  14. HOST DEFENSE AGAINST INTRACELLULAR INFECTION OF THE LUNG
    Shawn Skerrett; Fiscal Year: 2005
    ..This aim will test the hypothesis that bacterial dot/icm genes direct macrophage uptake of L. pneumophila by a pathway that results in diminished cellular activation in comparison bacteria deficient in these loci. ..
  15. Airway Inflammation: Bacterial Epithelial Interactions
    BRYAN HURLEY; Fiscal Year: 2004
    ..Results obtained from the following proposal may shed light on diseases involving bacterial mediated lung inflammation such as cystic fibrosis and should also provide new strategies directed towards treating lung disease. ..
  16. Regulatory Role of CTL-O2/Bcl2 in Epithelial Homeostasis
    H Cavanagh; Fiscal Year: 2006
    ..abstract_text> ..
  17. EXTRAMURAL FACILITIES IMPROVEMENT PROGRAM
    Robert Golden; Fiscal Year: 2004
    ....
  18. Novel Targets for Treatment of Pseudomonas aeruginosa
    Philip Lister; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  19. DEVELOPMENT OF A VACCINE FOR MORAXELLA CATARRHALIS
    Timothy Murphy; Fiscal Year: 2009
    ..catarrhalis surface, the identification of surface antigens expressed specifically during human infection and critical information about the human immune response to surface antigens of M. catarrhalis. ..
  20. P. aeruginosa lung disease in CF
    Anna Van Heeckeren; Fiscal Year: 2006
    ..These studies will direct future studies to more fully understand the pathophysiology of CF so novel treatments can be evaluated for use in CF patients. [unreadable] [unreadable]..
  21. MENTORED PATIENT ORIENTED RESEARCH CAREER DEVELOPMENT AW
    Margaret Rosenfeld; Fiscal Year: 2004
    ..The results and experience gained by the proposed studies may aid in the rigorous conduct of future clinical trials of inhaled agents in infants both with and without CF. ..
  22. The Role of BCL-2 in Corneal Epithelial Cell Shedding
    DANIELLE ROBERTSON; Fiscal Year: 2008
    ..4) That events leading to increased apoptosis such as UV light signal surface cell apoptosis through the phosphorylation of BCL-2. ..
  23. Recurrent otitis media and COPD: immunity and vaccines
    Timothy Murphy; Fiscal Year: 2004
    ..The proposed studies will advance the field of vaccine development to prevent otitis media and respiratory tract infections in COPD. ..
  24. Role of OxyR in P. aeruginosa Biofilm Resistance to H202
    DANIEL HASSETT; Fiscal Year: 2007
    ..unreadable] [unreadable]..
  25. B.pseudomallei bioterrorism and quorum sensing
    DANIEL HASSETT; Fiscal Year: 2003
    ..These studies will provide important information that will lead to countermeasures against a potential bioterrorist attack using the potentially lethal gram-negative bacterium, B. pseudomallei. ..
  26. Proteogenome of Anaerobic P. aeruginosa in CF Mucus
    DANIEL HASSETT; Fiscal Year: 2003
    ..Our LONG TERM GOAL is to identify cellular targets that inhibit or significantly compromise the denitrification process that is occurring by P. aeruginosa in the CF airways. ..
  27. IRON, FUR AND ALGINATE PRODUCTION IN P AERUGINOSA
    DANIEL HASSETT; Fiscal Year: 2002
    ..Information derived from the studies proposed herein will advance the current knowledge about the role of these factors in the pathogenesis of P. aeruginosa infections in CF. ..
  28. PGE2 Regulation of Epithelial/Fibroblast Interactions
    Bethany Moore; Fiscal Year: 2006
    ..abstract_text> ..
  29. Live Attenuated Recombinant Bacterial Delivery of Polysaccharide Vaccine Antigens
    Joanna B Goldberg; Fiscal Year: 2010
    ..We anticipate that this knowledge will also be applicable to other pathogens. ..
  30. Role of Inter-alpha Inhibitors in Anthrax Intoxication
    Steven Opal; Fiscal Year: 2007
    ..Our research is focused on the development of a new and safe treatment based on the ability of inter-alpha proteins to prevent the fatal consequences of anthrax infection. [unreadable] [unreadable] [unreadable] [unreadable]..
  31. ELR+ CXC CHEMOKINES IN PSEUDOMONAS AIRWAY INFECTION
    WAN TSAI; Fiscal Year: 2004
    ..End of Abstract) ..
  32. Redox control of Nrf2/ARE by thioredoxin and GSH
    Jason Hansen; Fiscal Year: 2005
    ..The roles of GSH and cytosolic and nuclear TRX during NRF2 activation and binding will provide an essential foundation for future developmental toxicology. ..
  33. Regulation of Alveolar Macrophage Phagocytosis
    Bruce Trapnell; Fiscal Year: 2006
    ..1, and Hck/SFKs in AMs. Results of this research are expected to help establish the feasibility of the therapeutic use of GM-CSF in the treatment of lung infections by a wide variety of microbial pathogens. ..
  34. Hospital-Acquired Infections in the Elderly
    Keith Kaye; Fiscal Year: 2008
    ..The risk factor identified for SSI and MDRB and the impact of SSI and MDRB on health outcomes will be used to design and implement future preventive interventions. ..
  35. Synthesis of P.Aeruginosa LPS and its Role in Infection
    JOANNA GOLDBERG; Fiscal Year: 2004
    ..The long-term goal of this research is to devise rational strategies to target LPS synthetic enzymes for the development of vaccines and antibacterial agents to inhibit infections caused by this important human pathogen. ..
  36. Pseudomonas invasion and the role of caveolin-2
    David Zaas; Fiscal Year: 2008
    ..A better understanding of these events is required for the eventual development of new adjunctive therapiesand possible prophylactic strategies for high risk patients. ..
  37. New Nosocomial Interventions to Decrease Antimicrobial Resistance Transmission
    Anthony Harris; Fiscal Year: 2008
    ..unreadable] [unreadable] [unreadable]..
  38. VIRULENCE AND IMMUNITY TO MUCOID P. AERUGINOSA
    Gerald Pier; Fiscal Year: 2009
    ..These aims will lead to further development of immunotherapeutics for P. aeruginosa infection in CF and evaluate alginate as an antigenic target for non-mucoid, as well as mucoid, P. aeruginosa infections. ..
  39. Pulmonary Alveolar Proteinosis Research Conference
    Bruce Trapnell; Fiscal Year: 2005
    ..This conference will provide a forum where thought leaders focused on the molecular and cellular basis or clinical management of PAP will present cutting edge research, integrate concepts, and chart innovative research directions. ..
  40. ROLE OF TIMPS AND MMPS IN CORNEAL ULCERATION
    KAREN KERNACKI; Fiscal Year: 2004
    ..Aim 4: To similarly examine specific TIMPs (TIMP-1 and -4) in the pathogenesis of corneal alkali-burn in inbred mice using moderate vs severe burns. ..
  41. Nasal carriage of S. aureus: host-pathogen interactions
    Alexander M Cole; Fiscal Year: 2010
    ..abstract_text> ..
  42. Retrocyclins: Circular Defensins Active Against HIV-1
    Alexander M Cole; Fiscal Year: 2010
    ..Availability of such agents, in the form of a cream or gel, would empower vulnerable sexual partners by providing them with an invisible, effective means of protection. ..
  43. LUNG INJURY, PERFLUOROCARBONS, AND HEMORRHAGIC SHOCK
    JOHN YOUNGER; Fiscal Year: 2003
    ....
  44. CXC CHEMOKINE REGULATION OF PROSTATE CANCER ANGIOGENESIS
    Bethany Moore; Fiscal Year: 2002
    ..These studies should lead to new insights into the biology of prostate cancer growth and metastasis, and pave the way to adapt adjuvant therapies for the treatment of this widespread disease. ..
  45. NOS GENE TRANSFER IN PULMONARY HYPERTENSION
    David Rodman; Fiscal Year: 2002
    ....
  46. Mucin Gene Regulation by Elastase and Oxidants
    Judith Voynow; Fiscal Year: 2008
    ..b. To determine whether NE and/or NQO1-generated ROS affect HuR binding to MUC5AC. c. To determine whether HuR binding is sufficient for MUC5AC mRNA stabilization. ..
  47. THE ROLE OF UROKINASE IN LUNG T LYMPHOCYTE RESPONSES
    MARGARET GYETKO; Fiscal Year: 2003
    ..Determine if recombinant uPA can reverse the functional abnormalities in uPA minus/minus lymphocytes. ..
  48. Helicobacter pylori LPS Signaling and Role in Chronicity
    JOANNA GOLDBERG; Fiscal Year: 2005
    ..pylori infections. Further we anticipate that deciphering the transcriptional and protein profiles resulting from H. pylori LPS will provide us with a framework to recognize the diagnostic features of chronic infections. ..
  49. Regulation of Innate Immunity by Virulence Factors
    Alejandro Aballay; Fiscal Year: 2006
    ..elegans. 3) Elucidate the mechanism by which the genes identified in Aims 1 and 2 contribute to C. elegans innate immunity pathways conserved in mammals. ..
  50. Improving Respiratory Outcomes in ALS
    Noah Lechtzin; Fiscal Year: 2006
    ..Lechtzin the opportunity to expand the skills required for development into an independent clinical investigator. ..
  51. AAT Deficiency & Liver Diseases Caused by Proteins
    Bruce Trapnell; Fiscal Year: 2006
    ..unreadable] [unreadable]..
  52. Genetic Modifiers in CF: Role of ABH polymorphisms
    JENNIFER TAYLOR COUSAR; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable]..
  53. Adaptive immunity of P. aeruginosa in cystic fibrosis
    GREGORY PRIEBE; Fiscal Year: 2006
    ..Knowledge gained from these studies will elucidate new strategies for the prevention and treatment of P. aeruginosa infections in the setting of CF. [unreadable] [unreadable] [unreadable]..
  54. Study design importance in analyzing emerging pathogens
    Anthony Harris; Fiscal Year: 2005
    ..The second aim will be done by combining epidemiological relatedness and molecular relatedness through pulse-field gel electrophoresis of ESBL cultures to quantify the importance of patient to patient transmission. ..
  55. Fourth Annual International Pulmonary Alveolar Proteinosis Research Conference
    Bruce Trapnell; Fiscal Year: 2006
    ..unreadable] [unreadable] [unreadable] [unreadable]..
  56. Noninvasive biomarkers of proteolytic activity in CF
    Scott Sagel; Fiscal Year: 2007
    ..In addition, he will actively participate and train in the Pediatric GCRC, and frequently interact with his sponsor, mentors, and collaborators. ..
  57. Invasion of the alveolar epithelium by Pseudomonas
    David Zaas; Fiscal Year: 2004
    ..3) Examine the specific role of caveolin-I in the endocytosis of invasive strains of Pa. ..
  58. THE ROLE OF APOPTOSIS IN CF PSEUDOMONAL LUNG INFECTION
    CAROLYN CANNON; Fiscal Year: 2004
    ..abstract_text> ..
  59. The Role of Wolbachia Endobacteria in River Blindness
    Eric Pearlman; Fiscal Year: 2008
    ..unreadable] [unreadable]..
  60. Transcriptional Regulation of a Surfactant Enzyme
    RAMA MALLAMPALLI; Fiscal Year: 2005
    ..Ultimately, the results from these studies could lead to therapeutic strategies directed at modulating expression of this key surfactant enzyme at the molecular level. ..
  61. Molecular Basis for Pseudomonas Recognition of Epithelia
    BARBARA KAZMIERCZAK; Fiscal Year: 2007
    ..unreadable] [unreadable]..